Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00441493
Status:
COMPLETED
Last Update Posted:
2012-07-27
First Post:
2007-02-27
Brief Title:
Fluvastatin Versus Hepatitis C Virus
Sponsor:
Bader Ted MD
Organization:
Bader Ted MD
Study Overview
Official Title:
A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a dose finding and efficacy trial for fluvastatin versus hepatitis C
Detailed Description:
Four different oral doses of fluvastatin will be used for 14 days and the viral load of hepatitis C will be measured weekly This has been extended to different doses for 9-12 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 13134 | None | None | None |